Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
Lijing Wang College of Life Sciences and Technology, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of ChinaCorrespondence: Lijing Wang, College of Life Science and Technology, China Pharmaceutical University, 639 Longmian Avenue, Jiangning District, Nanjing, Jiangsu,...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
Dove Medical Press,
2022-05-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Lijing Wang College of Life Sciences and Technology, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of ChinaCorrespondence: Lijing Wang, College of Life Science and Technology, China Pharmaceutical University, 639 Longmian Avenue, Jiangning District, Nanjing, Jiangsu, People’s Republic of China, Tel +86 182 860 69474, Email w359398300@gmail.com; 3220030021@stu.cpu.edu.cnAbstract: Improving type 2 diabetes using incretin analogues is becoming increasingly plausible. Currently, tirzepatide is the most promising listed incretin analogue. Here, I briefly explain the evolution of drugs of this kind, analyze the residue discrepancies between tirzepatide and endogenous incretins, summarize some existing strategies for prolonging half-life, and present suggestions for future research, mainly involving biased functions. This review aims to present some useful information for designing a dual glucagon like peptide-1 receptor/glucose-dependent insulinotropic polypeptide receptor agonist.Keywords: tirzepatide, GLP-1, GIP, Aib, structure–activity relationship, structure–function relationship |
|---|---|
| Item Description: | 1177-8881 |